Afaf E. Osman
( out of 31 reviews )

Afaf E. Osman, MD

Languages spoken: Arabic, English

  • Dr. Osman's clinical interest is in myeloid malignancies. Her research interest is in studying clonal hematopoiesis as a precursor condition to myeloid malignancies.

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 31 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 29, 2024
    HUNTSMAN CANCER CENTER

    Exelent and very professional

    September 12, 2024
    HUNTSMAN CANCER CENTER

    I'm very pleased to have Dr. Osman as my Dr.

    July 07, 2024
    HUNTSMAN CANCER CENTER

    Dr. Osman seems to be very thorough and I can tell that she cares about my health.

    June 17, 2024
    HUNTSMAN CANCER CENTER

    Dr Osman understands and listens to my issues.Excellent and concerned Dr

    June 16, 2024
    HUNTSMAN CANCER CENTER

    Very caring doctor that listens to her patients. Makes decisions based on facts.

    May 27, 2024
    HUNTSMAN CANCER CENTER

    Dr. Osman is thorough and works very hard at figuring out how to treat my disease/disorder. I like how she sits down and discusses labs/test results; and draws out treatment options on paper. She is personable and caring. Plus she has a wonderful team supporting her.

    May 17, 2024
    HUNTSMAN CANCER CENTER

    Dr. Osman is very thoughtful and caring. She sits down with me to explain labs, tests, treatment plan and options. I'm grateful she is guiding me through this journey!

    April 29, 2024
    HUNTSMAN CANCER CENTER

    Very Professional yet Very Personable - Everything you want in a Doctor

    March 24, 2024
    HUNTSMAN CANCER CENTER

    Dr. Osman explains everything clearly and takes the time to explain if you don't understand.

    See More Patient Comments

  • Dr. Osman's clinical interest is in myeloid malignancies. Her research interest is in studying clonal hematopoiesis as a precursor condition to myeloid malignancies.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Leukemia - University of Chicago Research Fellow
    Hematology & Oncology - University of Chicago Clinical Fellow
    Residency Internal Medicine - Johns Hopkins Hospital Resident
    Medicine - Weill Cornell Medical College in Qatar M.D.
    Certification Premedical Program - Weill Cornell Medical College in Qatar Pre Med

    Selected Publications

    Journal Article

    1. Dravillas CE, Coleman SS 4th, Hoyd R, Caryotakis G, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC, exORIEN Consortium (2023). The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors. Cancer Res Commun, 4(8), 1978-1990. (Read full article)
    2. Xie Z, Komrokji RS, Al-Ali N, Regelson A, Geyer S, Patel AA, Saygin C, Zeidan AM, Bewersdorf JP, Mendez LM, Kishtagari A, Zeidner JF, Coombs CC, Madanat YF, Chung SS, Badar T, Foran JM, Desai P, Tsai C, Griffiths EA, Al Malki MM, Amanam I, Lai C, Deeg HJ, Ades L, Arana-Yi C, Osman AE, Dinner SN, Abaza Y, Taylor J, Chandhok NS, Soong D, Brunner AM, Carraway HE, Singh A, Elena C, Ferrari J, Galli A, Pozzi S, Padron E, Patnaik MM, Malcovati L, Savona MR, Al-Kali A (2024). Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence. Blood. (Read full article)
    3. Benej M, Hoyd R, Kreamer M, Wheeler CE, Grencewicz DJ, Choueiry F, Chan CHF, Zakharia Y, Ma Q, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Robinson LA, Singer EA, Ikeguchi AP, McCarter MD, Tinoco G, Husain M, Jin N, Tan AC, Osman AEG, Eljilany I, Riedlinger G, Schneider BP, Benejova K, Kery M, Papandreou I, Zhu J, Denko N, Spakowicz D, exORIEN Consortium (2023). The Tumor Microbiome Reacts to Hypoxia and Can Influence Response to Radiation Treatment in Colorectal Cancer. Cancer Res Commun, 4(7), 1690-1701. (Read full article)
    4. Osman AEG, Rets A, Patel AB (2024). KRAS mutations, autoimmunity and female sex in chronic myelomonocytic leukemia. Leuk Res, 138, 107466. (Read full article)
    5. Wang C, Ma A, Li Y, McNutt ME, Zhang S, Zhu J, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q, exORIEN Consortium (2023). A Bioinformatics Tool for Identifying Intratumoral Microbes from the ORIEN Dataset. Cancer Res Commun, 4(2), 293-302. (Read full article)
    6. Wheeler CE, Coleman SS 4th, Hoyd R, Denko L, Chan CHF, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AEG, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC (2023). The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors. (Read full article)
    7. Wang C, Ma A, McNutt ME, Hoyd R, Wheeler CE, Robinson LA, Chan CHF, Zakharia Y, Dodd RD, Ulrich CM, Hardikar S, Churchman ML, Tarhini AA, Singer EA, Ikeguchi AP, McCarter MD, Denko N, Tinoco G, Husain M, Jin N, Osman AEG, Eljilany I, Tan AC, Coleman SS 4th, Denko L, Riedlinger G, Schneider BP, Spakowicz D, Ma Q (2023). A bioinformatics tool for identifying intratumoral microbes from the ORIEN dataset. (Read full article)
    8. Osman AEG, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, Pozsgai M, Sinha E, Chandra P, Hassane DC, Sboner A, Sangani K, DiNardi N, Johnson C, Wallace SS, Jabri B, Luu H, Guzman ML, Desai P, Godley LA (2022). Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Adv, 7(9), 1910-1914. (Read full article)
    9. Osman A, Mencia-Trinchant N, Saygin C, Moma L, Kim A, Housman G, Pozsgai MJ, Sinha E, Chandra P, Hassane DC, Sboner A, Sangani K, DiNardi N, Johnson C, Wallace SS, Jabri B, Luu H, Guzman ML, Desai P, Godley LA (2022). Paired bone marrow and peripheral blood samples demonstrate lack of widespread dissemination of some CH clones. Blood Adv, 7(9), 1910-1914. (Read full article)
    10. Yu B, Osman AEG, Sladojevic N, Prabhu N, Tai HC, Chen D, Perla G, Park L, Larson RA, Liao JK (2022). Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity. JACC CardioOncol, 4(3), 371-383. (Read full article)
    11. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey AT (2021). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. Clin Neurol Neurosurg, 212, 107064. (Read full article)
    12. Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp NJ (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. J Transl Genet Genom, 5, 189-199. (Read full article)
    13. Feurstein S, Adegunsoye A, Mojsilovic D, Vij R, DePersia AHW, Rajagopal PS, Osman A, Collins RH, Kim RH, Gore SD, Greenberg P, Godley LA, Li Z, Del Gaudio D, Subramanian HP, Das S, Walsh T, Gulsuner S, Segal JP, Husain AN, Gurbuxani S, King MC, Strek ME and Churpek JE (2020). Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations. Blood Adv, 4(19), 4873-4886.
    14. Osman A, Gocke CD, Gladstone DE (2016). Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones. Clin Lymphoma Myeloma Leuk, 17(2), 97-99. (Read full article)
    15. Osman A, et al (2014). Sudden Worsening of DRESS Syndrome on Tapering Steroid Dose with Dramatic Improvement on N-acetylcysteine and Steroid Dose Escalation. 6(2), 101-10.

    Review

    1. Liu J, Osman AEG, Bolton K, Godley LA (2023). Germline predisposition to clonal hematopoiesis. [Review]. Leuk Res, 132, 107344. (Read full article)
    2. Croci DM, Gamboa NT, Osman AEG, Maese L, Mazur M, Bisson EF, Dailey AT (2021). Solitary manifestations of primary B-lymphoblastic lymphoma of the spine: Systematic literature review with case illustration. [Review]. Clin Neurol Neurosurg, 212, 107064. (Read full article)
    3. Osman AEWG (2021). When are idiopathic and clonal cytopenias of unknown significance (ICUS or CCUS)? [Review]. Hematology Am Soc Hematol Educ Program, 2021(1), 399-404. (Read full article)
    4. Osman AEG, Deininger MW (2021). Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. [Review]. Blood Rev, 49, 100825. (Read full article)
    5. Osman A, Patel JL (2021). Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. [Review]. Clin Chem, 67(8), 1062-1070. (Read full article)
    6. Osman AEG, Luke JJ (2019). The Impact of the Fecal Microbiome on Cancer Immunotherapy. [Review]. BioDrugs, 33(1), 1-7. (Read full article)
    7. Akpan IJ, Osman AEG, Drazer MW, Godley LA (2018). Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies. [Review]. Curr Hematol Malig Rep, 13(6), 426-434. (Read full article)
    8. Osman AEG, Anderson J, Churpek JE, Christ TN, Curran E, Godley LA, Liu H, Thirman MJ, Odenike T, Stock W, Larson RA (2018). Treatment of Acute Promyelocytic Leukemia in Adults. [Review]. J Oncol Pract, 14(11), 649-657. (Read full article)

    Case Report

    1. Osman A, Galiatsatos P, Bose S, Danoff S (2017). Rheumatoid arthritis causing diffuse alveolar haemorrhage: a novel therapeutic approach. BMJ Case Rep, 2017. (Read full article)

    Abstract

    1. Osman AYu B, Glavin N, Polonsky T, Liao J, Larson RA (2018). ABL Tyrosine Kinase Inhibitors (TKIs) are Associated with Increased Rho-Associated Kinase (ROCK) Activity that May Contribute to Vascular Toxicity in Patients with Chronic Myeloid Leukemia (CML). Poster session: 632 Chronic Myeloid Leukemia: Therapy, American Society of Hematology 60th Annual Meeting, San Diego, CA [Abstract]. 132(Suppl 1), 1739.
    2. Osman AGaliatsatos PBose S (2017). Diffuse Alveolar Hemorrhage as a Rare Manifestation of Rheumatoid Arthritis. Poster session presented at the Autoimmune Lung Disease: Case Reports Thematic Poster Session. American Thoracic Society International Conference, Washington, DC [Abstract]. 195, A1460.

    Other

    1. Osman AEG, Luke JJ (2019). The Gut Microbiome and Cancer Immunotherapy. (4(8), pp. 14, 15).